[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338766-105":59,"doc-detail-338766-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cellular-liquid-biopsy-provides-unique-chances-for-disease-monitoring-preclinical-model-generation-and-therapy-adjustment-in-rare-salivary-gland-cancer-patients","Cellular liquid biopsy provides unique chances for disease monitoring - preclinical model generation and therapy adjustment in rare salivary gland cancer patients","","Cellular liquid biopsy (cLB) enables molecular genetic assessment of systemic disease heterogeneity and supports preclinical model development, complementing simpler and cheaper cell-free liquid biopsy (cfLB) for disease monitoring. The study analyzed 71 blood samples from 62 patients with advanced cancers and derived enriched circulating tumor cell (CTC) organoids (tumoroid cultures). Tumoroid models were characterized by sequencing, immunohistochemistry, and functional drug testing, linking CTC features to primary tumors and metastases. CTC enumeration correlated with disease progression, with tumoroid formation observed in only salivary gland cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cellular-liquid-biopsy-provides-unique-chances-for-disease-monitoring-preclinical-model-generation-and-therapy-adjustment-in-rare-salivary-gland-cancer-patients/338766/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cellular-liquid-biopsy-provides-unique-chances-for-disease-monitoring-preclinical-model-generation-and-therapy-adjustment-in-rare-salivary-gland-cancer-patients/338766.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does cellular liquid biopsy differ from cell-free liquid biopsy in this study?","Question",{"text":112,"@type":113},"Cell-free liquid biopsy focuses on simpler analytes for monitoring, while cellular liquid biopsy adds cellular genetic assessment, enabling evaluation of systemic heterogeneity and development of preclinical models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What experimental approach was used to generate disease models?",{"text":117,"@type":113},"Enriched circulating tumor cells were cultured under organoid conditions to produce CTC-derived tumoroid models.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship was observed between CTC counts and patient disease progression?",{"text":121,"@type":113},"CTC enumeration was linked to disease progression, and in one salivary gland cancer patient longitudinal counts reflected progression and detected metastatic relapse earlier than clinical imaging.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338766,1790077466,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Cellular liquid biopsy provides unique chances for disease  \nmonitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients Nataˇsa Stojanovi´c Guˇzvi´c1, Florian L u¨ke 1,2,3, Stefﬁ Treitschke 1, Andrea Coluccio 1, Martin Hoffmann 1, Giancarlo Feliciello 1, Adithi Ravikumar Varadarajan 1 , Xin Lu 1,  \nKathrin Weidele 1 , Catherine Botteron 1, Silvia Materna–Reichelt 1, Felix Keil3,4, Katja Evert3,4, Florian Weber 1,3,4, Thomas Schamberger5, Michael Althammer5, Jirka Grosse3,6, Dirk Hellwig3,6, Christian Schulz3,7, Stephan Seitz3,8, Peter Ugocsai3,8, Anke Schlenska-Lange9, Roman Mayr 10, Ulrich Kaiser2,3, Wolfgang Dietmaier4, Bernhard Polzer 1, Jens Warfsmann 1, Kamran Honarnejad 1, Tobias Pukrop 1,2,3, Daniel Heudobler2,3, Christoph A. Klein 1,3,5  and Christian Werno 1   \n1 Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany  \n2 Department of Internal Medicine III, University Hospital Regensburg, Germany  \n3 Bavarian Cancer Research Center (BZKF), Regensburg, Germany  \n4 Insitute for Pathology, University of Regensburg, Germany  \n5 Experimental Medicine and Therapy Research, University of Regensburg, Germany  \n6 Department of Nuclear Medicine, University Hospital Regensburg, Germany  \n7 Department of Internal Medicine II, University Hospital Regensburg, Germany  \n8 Department of Obstetrics and Gynecology, University Hospital Regensburg, Germany  \n9 Department of Oncology and Hematology, Hospital Barmherzige Bru¨der, Regensburg, Germany  \n10 Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Germany  \nKeywords  \nCTC; liquid biopsy; personalized tumor therapy; salivary gland cancer; tumoroid culture  \nCorrespondence  \nC. A. Klein, Experimental Medicine and Therapy Research, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany  \nTel: +49 941 944 31220  \nE-mail: [christoph.klein@ukr.de](christoph.klein@ukr.de)[ ](christoph.klein@ukr.de)and  \nC. Werno, Fraunhofer-ITEM, Division of Personalized Tumour Therapy, Am Biopark  \n9, 93053 Regensburg, Germany  \nTel: +49 941 298480 54  \nE-mail: [christian.werno@item.fraunhofer.de](christian.werno@item.fraunhofer.de)  \nWhile cell-free liquid biopsy (cfLB) approaches provide simple and inexpensive disease monitoring, cell-based liquid biopsy (cLB) may enable additional molecular genetic assessment of systemic disease heterogeneity and preclinical model development. We investigated 71 blood samples of 62 patients with various advanced cancer types and subjected enriched circulating tumor cells (CTCs) to organoid culture conditions. CTC-derived tumoroid models were characterized by DNA/RNA sequencing and immunohistochemistry, as well as functional drug testing. Results were linked to molecular features of primary tumors, metastases, and CTCs; CTC enumeration was linked to disease progression. Of 52 samples with positive CTC counts (≥1) from eight different cancer types, only CTCs from two salivary gland cancer (SGC) patients formed tumoroid cultures (P = 0.0005) . Longitudinal CTC enumeration of one SGC patient closely reﬂected disease progression during treatment and revealed metastatic relapse earlier than clinical imaging. Multiomics analysis and functional in vitro drug testing identiﬁed potential resistance mechanisms and drug  \nAbbreviations  \nAdCC, adenoid cystic carcinoma; AR, androgen receptor; cfLB, cell-free liquid biopsy; cLB, cellular liquid biopsy; CTC, circulating tumor cell; CNA, copy number alteration; EpCAM, epithelial cell adhesion molecule; EGFR, epithelial growth factor receptor; FDG PET/CT,ﬂuorodeoxyglucose positron emission tomography/computerized tomography; FFPE, formalin-ﬁxed, parafﬁn-embedded; GSEA, gene set enrichment analysis; HE, hematoxylin eosin; IHC, immunohistochemistry; KEGG, Kyoto Encyclopedia of Genes and Genomes; LN, lymph node; m, month; PT, primary tumor; SCNEC, small cell neuroendocrine carcinoma; SCLC, small cell lung cancer; S","cbCaiplVY9KKLeEg","https://ap.wps.com/l/cbCaiplVY9KKLeEg","pdf",13660384,18,"English","# Introduction\n## Blood-derived liquid biopsy for disease monitoring\n## Limits and potential of cellular liquid biopsy\n# Results\n## Tumoroid culture formation from CTCs\n## CTC enumeration and disease progression","[{\"question\":\"How does cellular liquid biopsy differ from cell-free liquid biopsy in this study?\",\"answer\":\"Cell-free liquid biopsy focuses on simpler analytes for monitoring, while cellular liquid biopsy adds cellular genetic assessment, enabling evaluation of systemic heterogeneity and development of preclinical models.\"},{\"question\":\"What experimental approach was used to generate disease models?\",\"answer\":\"Enriched circulating tumor cells were cultured under organoid conditions to produce CTC-derived tumoroid models.\"},{\"question\":\"What relationship was observed between CTC counts and patient disease progression?\",\"answer\":\"CTC enumeration was linked to disease progression, and in one salivary gland cancer patient longitudinal counts reflected progression and detected metastatic relapse earlier than clinical imaging.\"}]","Cellular liquid biopsy provides unique chances for disease monitoring - preclinical model generation and therapy adjustment in rare salivary gland cancer patients | PDF",1790025515,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d8dd696215741f6d58045d409055e7.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fd98ccb06bfb662a2140c134f70b8e3.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61fdd3f48fc879a9cafd6acbd3915715.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7a29f1b123b1c4732dcfd8b584dc5d2.webp",980,1287]